Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) released a report onDecember 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activit...
Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatme...
'Curing Cancer without Surgery'
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...
